Latest News, Press Releases & Events

Spyryx Biosciences Expands with Election of Roger Jeffs, PhD as Independent Director

– Recognized Biotech Leader With Extensive Experience in Respiratory Product Development and Rare Diseases DURHAM, N.C., Jan. 16, 2018 /PRNewswire/ — Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for severe pulmonary diseases, announced today the election of Dr. Roger Jeffs as a member of the Company’s board of directors. Dr. Jeffs brings […]

Continue Reading

Positive Pre-Clinical Data Supporting SPX-101 to be Presented at the North American Cystic Fibrosis Conference

4 Posters detail SPX-101’s unique mechanism and potential to provide clinically meaningful benefit for all people with cystic fibrosis DURHAM, N.C., Nov. 1, 2017 /PRNewswire/ — Spyryx Biosciences, Inc., will share positive data this week highlighting additional insights into the mechanism of action and pharmacological importance of SPX-101, the Company’s pipeline therapeutic treatment for cystic fibrosis […]

Continue Reading

Spyryx Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of SPX-101 for the Treatment of Cystic Fibrosis

DURHAM, N.C., October 18, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe respiratory diseases, today announced the first patient was dosed in the HOPE-1 study, a multinational Phase 2 clinical trial for its lead compound, SPX-101 in cystic fibrosis (CF). HOPE-1 is a 28-day study using an adaptive […]

Continue Reading